DRC Ebola outbreak spreads to sixth province
Analysis based on 543 articles · First reported Mar 09, 2018 · Last updated Aug 14, 2026
The outbreak is straining healthcare systems in Central Africa and prompting significant international funding and vaccine development efforts, which could benefit pharmaceutical companies involved in Ebola research. However, the direct impact on global financial markets is limited, with the main effects seen in increased government spending and potential disruptions to regional trade and travel.
The Democratic Republic of the Congo is experiencing its largest and fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there are no approved vaccines or treatments. The outbreak, declared on May 15, 2026, has spread to a sixth province, Democratic Republic of the Congo — Bas-Uélé, after a traveler from Ituri died there. As of mid-August, the outbreak has killed over 2,100 people out of more than 4,500 confirmed cases, with a case fatality rate of about 45%. The World Health Organization has declared it a Public Health Emergency of International Concern and warns it is on track to surpass the deadliest Ebola outbreak in history (2014-2016 West Africa). The response is hampered by conflict, community mistrust, misinformation, and strikes by unpaid health workers. Vaccine and treatment trials are underway, including a WHO-recommended trial of the RVSV-ZEBOV vaccine vaccine for cross-protection, and candidate vaccines from Oxford, Moderna, and Hilleman Laboratories. The United States has committed over $500 million in aid. Uganda declared its own linked outbreak over in late July.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard